Medication Possession Ratio Associated with Short-Term Virologic Response in Individuals Initiating Antiretroviral Therapy in Namibia

Hong, Steven Y.; Jerger, Logan; Jonas, Anna; Badi, Alfons; Cohen, Steven; Nachega, Jean B.; Parienti, Jean-Jacques; Tang, Alice M.; Wanke, Christine; Terrin, Norma; Pereko, Dawn; Blom, Abraham; Trotter, Andrew B.; Jordan, Michael R.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
The visual-analogue scale (VAS), Likert item (rating scale), pills identification test (PIT), and medication possession ratio (MPR) provide estimates of antiretroviral therapy (ART) adherence which correlate with HIV viral suppression. These simple adherence measures are inexpensive and easy to administer; however, require validation and adjustment prior to implementation. The objective of this study was to define the optimal adherence assessment measure in Namibia to identify patients at risk for sub-optimal adherence and poor virologic response 6 months after ART initiation. We conducted a cross-sectional survey in HIV-infected adults receiving ART for 6–12 months prior to the adherence assessment. Adherence measures included 30-day VAS, 30-day Likert item, self-reported treatment interruptions, PIT, and MPR. Association of adherence measures with 6-month HIV-1 RNA level was assessed using two thresholds (1000 copies/mL and 5000 copies/mL). Adherence was assessed in 236 patients, mean age 37.3 years, 54% female. Mean adherence was 98.1% by 30-day VAS, 84.7% by 30-day Likert item, 97.0% by self-reported treatment interruptions, 90.6% by PIT, and 98.8% by MPR. Agreement between adherence measures was poor using kappa statistic. 76% had HIV-1 RNA <1000 copies/ml, and 88% had HIV-1 RNA <5000 copies/ml. MPR (continuous) was associated with viral suppression <5000 copies/ml (p = 0.036). MPR <75% was associated with virologic failure at ≥5000 copies/ml with OR 3.89 (1.24, 12.21), p = 0.013. Adherence was high with all measures. Only MPR, was associated with short-term virologic response, suggesting its cross-culturally utility for early identification of patients at high risk for virologic failure.


Related Articles

  • MATHEMATICAL MODELS FOR THE STUDY OF HIV/AIDS EPIDEMIC. Vasanthi, T.; Vijayalakshmi, V.; Nisha, L. Jannathun // Bio Science Research Bulletin-Biological Sciences;Jul-Dec2012, Vol. 28 Issue 2, p93 

    Mathematical models here serve as tools for understanding the epidemiology of Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) if they are carefully constructed. This paper deals with the spread of STDs infections and in particular HIV epidemics. This article...

  • HIV/AIDS IN EASTERN EUROPE: MORE THAN A SEXUAL HEALTH CRISIS. Lazarus, Jeffrey V.; Bollerup, Annemarie; Srdan Matić, Srdan // Central European Journal of Public Health;2006, Vol. 14 Issue 2, p55 

    HIV/AIDS is often described as a sexually transmitted disease. In the former USSR, however, the HIV/AIDS epidemic is being driven by injecting drug use among men. This article addresses several widely circulated assumptions about HIV in eastern Europe: that sexual contact is the primary mode of...

  • Suministro de antirretrovirales en Argentina: Programa Nacional de Lucha contra los Retrovirus del Humano, SIDA y ETS. Colautti, Marisel; Luppi, Irene; Salamano, Mercedes; Traverso, María Luz; Botta, Carina; Palchik, Valeria // Revista Panamericana de Salud Publica;Jan2009, Vol. 25 Issue 1, p62 

    Objectives. To evaluate the supply cycle of antiretroviral (ARV) drugs, overseen by the National Program to Combat Human Retroviruses, AIDS, and STDs, through its order fulfillment indicators, and to obtain input from supply chain stakeholders. Methods. A study was carried out from...

  • HIV Digest.  // Guide;Jun2005, Vol. 25 Issue 6, p39 

    Presents trends and developments on HIV treatment. Possible therapeutic benefits and applications of highly active antiretroviral therapy as treatment for infection-related cancers; Testing of the HIV drug tenofovir to HIV-negative men who have sex with men; Results of a Canadian study which...

  • High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy. Pyoeng Gyun Choe; Hyung Jin Choi; Nak-Hyun Kim; Wan Beom Park; Kyoung-Ho Song; Ji Hwan Bang; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Myoung-don Oh; Nam Joong Kim // Journal of the International AIDS Society;2014, Vol. 17, p1 

    Introduction: Low bone mass is prevalent in HIV-positive patients. However, compared to Western countries, less is known about HIV-associated osteopenia in Asian populations. Methods: We performed a cross-sectional survey in Seoul National University Hospital from December 2011 to May 2012. We...

  • Barriers and Facilitators for Adherence to Antiretroviral Therapy in Papua New Guinea. Kelly, A.; Worth, H.; Man, N.; Nosi, S.; Emori, R.; Mek, A.; Akuani, F.; Kupul, M.; Kepa, B.; Walizopa, L.; Pirpir, L.; Cangah, B.; Siba, P.; Frankland, A.; Rawstorne, P. // Current HIV Research;Dec2010, Vol. 8 Issue 8, p630 

    No abstract available.

  • Non-Specific Microbicide Product Development: Then and Now. Romano, Joseph W.; Robbiani, Melissa; Doncel, Gustavo F.; Moench, Thomas // Current HIV Research;Jan2012, Vol. 10 Issue 1, p9 

    Despite the identification of HIV-1 as the etiological agent responsible for AIDS nearly 30 years ago, a sterilizing vaccine capable of preventing transmission of the virus remains elusive. In response to struggles on the vaccine development front, significant effort has been devoted to...

  • Ask he Pharmacist. Oviawe, Marvin // Word (Word Publications - Ted Fleischaker);Jan2011, p27 

    The author discusses the need to take medications on time in order to assure favorable outcomes in HIV patients. He says that patient readiness to begin taking HIV medications on time is a critical step in keeping HIV/AIDS under control. He adds that the chance of surviving longer increases when...

  • SUMMARY REPORT: TREATING HIV/AIDS. Rabah, Raida // Ethnicity & Disease;Summer2007 Supplement 3, Vol. 17, pS3100 

    The article discusses some advances in treating HIV/AIDS. It is estimated that only eight percent of the four million infected people in Africa are receiving antiretrovirals. Drugs that target different stages and steps in viral replications have been developed and are best used in combinations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics